Combination Vaccine Products Lead Pediatric Vaccine Sales, says Kalorama Information Report

Sept. 16, 2010 - PRLog -- Combination vaccines containing of variety of antigens are dominating the pediatric category of vaccine sales and will continue to do so in the near future, according to a new report from Kalorama Information, and many companies are competing for a slice of the market.   The vaccines prevent several different diseases or protects against multiple strains of infectious agents causing the same disease.  According to Kalorama Information in its recent report Vaccines 2010: World Market Analysis, Key Players, and Critical Trends in a Fast-Changing Industry, sales of these drugs make up one-fifth of the vast pediatric vaccine market.  

The components of these combination products vary depending on needs in various parts of the world. Today, combination vaccines protect against up to seven diseases: diphtheria, tetanus, pertussis (whooping cough), polio, hepatitis B, varicella and Haemophilus influenzae type b (Hib), which is associated with meningitis. Through 2014, sales growth of DTP and DTaP vaccines will slow on increasing preference for vaccines that protect against these and other diseases. The DTP vaccine, which contains whole-cell pertussis, was phased out in Japan, North America, and most European countries in the 1990’s, but continues to be used in some developing nations.

A large number of manufacturers offer combination products. Pediarix (GlaxoSmithKline), approved in the U.S. in 2002, was the first FDA-approved vaccine to offer protection against five diseases simultaneously, reducing the total number of shots infants receive by up to six.  GlaxoSmithKline also sells Boostrix, a booster immunization against tetanus, diphtheria and pertussis as a single dose in adolescents. Other leading products include Sanofi Pasteur’s Daptacel and Pediacel, which contain an acellular pertusis valance and protect against a variety of diseases including pertusis. In 2008, the FDA licensed Sanofi Pasteur’s Daptacel vaccine for the fifth consecutive dose in the pediatric DTaP immunization series, allowing the vaccine to be utilized for the entire immunization series to protect against diphtheria, tetanus, and pertussis, enabling health care professionals to administer the same brand of DTaP vaccines.  These new products are among those that will drive growth, according to Kalorama.

More information can be found in Kalorama Information’s report, Vaccines 2010: World Market Analysis, Key Players, and Critical Trends in a Fast-Changing Industry.  The report can be found at: http://www.kaloramainformation.com/Vaccines-Key-Players-2....

# # #

About Kalorama Information
Kalorama Information (www.kaloramainformation.com) supplies the latest in independent market research in the life sciences, as well as a full range of custom research services. We routinely assist the media with healthcare topics. Follow us on Twitter: www.twitter.com/KaloramaInfo.

Please direct all media inquiries to:
Andrea Hiller
Marketing Manager
(212) 807-2673
press@kaloramainformation.com
www.kaloramaInformation.com